Skip to content
HowShorted

Zynerba Pharmaceuticals, Inc. short interest in 2020

In 2020, Zynerba Pharmaceuticals, Inc.'s disclosed short interest ran from 27.53% of shares outstanding on 15 Jan 2020 to 14.38% on 31 Dec 2020, a change of -13.15 percentage points. The year's high was 29.77% on 30 Jun 2020 and its low 12.60% on 13 Nov 2020, averaging 21.36% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.49 days on 14 Feb 2020. Full history: Zynerba Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for Zynerba Pharmaceuticals, Inc. in 2020

2020 in figures

Start of year
27.53% (15 Jan 2020)
End of year
14.38% (31 Dec 2020)
Change
-13.15 pp
High
29.77% (30 Jun 2020)
Low
12.60% (13 Nov 2020)
Average
21.36%
Highest days to cover
17.49 (14 Feb 2020)
SEC filings marked
8

Every report in 2020

Zynerba Pharmaceuticals, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202027.53%10.95
31 Jan 202028.04%13.15
14 Feb 202028.48%17.49
28 Feb 202028.93%8.08
13 Mar 202027.46%12.5710-K filed, results (8-K)
31 Mar 202024.19%11.53
15 Apr 202023.90%16.74
30 Apr 202023.08%11.51
15 May 202024.44%5.7210-Q filed, results (8-K)
29 May 202025.53%3.56
15 Jun 202028.82%5.86
30 Jun 202029.77%2.83
15 Jul 202025.83%3.14
31 Jul 202023.25%7.83
14 Aug 202017.49%8.3410-Q filed, results (8-K)
31 Aug 202014.81%9.11
15 Sep 202013.43%12.44
30 Sep 202014.98%6.95
15 Oct 202014.79%15.43
30 Oct 202014.93%11.05
13 Nov 202012.60%6.9710-Q filed, results (8-K)
30 Nov 202013.19%6.92
15 Dec 202012.87%7.17
31 Dec 202014.38%2.64

See also: Zynerba Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.